|
SAN DIEGO, Nov. 18 /PRNewswire/ -- Ascenta Therapeutics Inc., a
privately-held clinical stage biopharmaceutical company today announced the
presentation of three key pipeline programs at the International Conference on
Molecular Targets and Cancer Therapeutics in Philadelphia, PA, jointly held by
the American Association for Cancer Research (AACR), the National Cancer
Institute (NCI) and the European Organization for Research and Treatment of
Cancer (EORTC).
Ascentas lead compound AT-101, an orally bioavailable pan-Bcl-2
inhibitor, is currently in Phase II clinical trials and clinical trial data
was presented on this product at the conference. Ascenta and its
collaborators at the University of Michigan also presented new data on three
small-molecule agents against several targets in the companys pipeline:
ApoG2, an orally bioavailable pan-Bcl-2 inhibitor with uniquely potent
activity against the Mcl-1 protein; SM-122 (SH-122), a potent and specific
Smac mimetic designed to target multiple inhibitors of apoptosis proteins
(IAPs); and MI-43, a potent, highly specific antagonist of the p53-MDM2
protein interaction.
"These three compounds hit highly novel and scientifically relevant
targets in key apoptosis pathways," said Dr. Dajun Yang, Vice President of
Research at Ascenta. "They speak to the strength of Ascentas portfolio of
next-generation products for the treatment of cancer."
Founded in 2003, Ascenta is a privately-held biopharmaceutical company
that discovers and develops targeted new medicines for the treatment of
cancer. The company has offices in San Diego, California and a preclinical
research facility in Shanghai, China. Ascentas technology is focused on
discovering molecules that hit vulnerable targets in endogenous apoptosis
pathways and shut down cell growth and proliferation in cancer cells.
Ascentas clinical lead compound and broad pipeline of compounds are licensed
from the laboratory of Dr. Shaomeng Wang at the University of Michigan and the
National Institutes of Health.
|
|
